Skip to main content
Clinical Trials/NCT06422481
NCT06422481
Not Yet Recruiting
N/A

Non-invasive Measurement of Myocardial Work Using Transthoracic Echocardiography in Critically Ill Patients: the MYOLOAD Study

Centre Hospitalier Universitaire de Nice3 sites in 1 country110 target enrollmentJuly 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cardiovascular Physiological Phenomena
Sponsor
Centre Hospitalier Universitaire de Nice
Enrollment
110
Locations
3
Primary Endpoint
Determine the feasibility of echocardiographic measurement
Status
Not Yet Recruiting
Last Updated
last year

Overview

Brief Summary

Echocardiography is recommended for the hemodynamic management of patients with shock. Recently, a new echocardiographic method has been proposed that provides a non-invasive measurement of myocardial work incorporating different components, namely total myocardial work (GWI), constructive myocardial work (GCW), lost myocardial work (GWW) and effective myocardial work (GWE). Echocardiographic measurement of myocardial work takes into account both myocardial deformation and left ventricular afterload (estimated by measuring systolic blood pressure) and, unlike the measurement of left ventricular ejection fraction and global longitudinal strain, could be less dependent on cardiac load conditions, particularly left ventricular afterload. To date, non-invasive measurement of myocardial work has never been validated in critically ill patients, and no study has assessed the effects of different therapies (fluids administration, administration of norepinephrine) on the different components of myocardial work in patients admitted to intensive care unit.

Registry
clinicaltrials.gov
Start Date
July 2024
End Date
December 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Indication to fluid administration left to the discretion of the attending physician
  • Indication to norepinephrine administration or increase in norepinephrine dosage left to the discretion of the attending physician.

Exclusion Criteria

  • Patients under protection.
  • Patients with do not ressuscitate order.
  • Patients with severe left-side or right-side valvulopathy.
  • Patients with atrial fibrillation.
  • Patients with ventricular aneuvrysm or severe regional wall motion abnormalities.
  • Patients with a pacemaker.
  • Patients' objections to the collection of their health data.

Outcomes

Primary Outcomes

Determine the feasibility of echocardiographic measurement

Time Frame: through study completion, an average of 1 year

The primary outcome will be assess by evaluating the proportion of patients in whom non-invasive echocardiographic measurement of myocardial work is obtained.

Secondary Outcomes

  • measurement of myocardial by cardiac ultrasound during fluid administration(through study completion, an average of 1 year)
  • measurement of myocardial by cardiac ultrasound norepinephrine administration(through study completion, an average of 1 year)

Study Sites (3)

Loading locations...

Similar Trials